This is a summary of the European public assessment report (EPAR) for Zypadhera. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zypadhera.
Therapeutic Indication
### Therapeutic indication Maintenance treatment of adult patients with schizophrenia sufficiently stabilised during acute treatment with oral olanzapine.
Therapeutic Area (MeSH)
N/AATC Code
N05AH03
ATC Item
olanzapine
Pharmacotherapeutic Group
Psycholeptics
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| olanzapine pamoate | N/A | Olanzapine pamoate |
EMA Name
Zypadhera
Medicine Name
Zypadhera
Aliases
N/ANo risk management plan link.
